ABSTRACT: One year
■ INTRODUCTION
The overall goals for the Human Proteome Project (HPP) are:
(1) to complete in stepwise fashion the Protein Parts List − identifying and characterizing at least one protein product and as many PTM, SAP, and splice variant isoforms as possible from each of the full complement of human protein-coding genes and (2) to make proteomics a more useful counterpart to genomics by enhancing the work of the entire biomedical research community with high-throughput robust instruments, reagents, specimens, preanalytical protocols, and knowledge bases for identification, quantification, and characterization of proteins in network context in a broad array of biological systems.
1,2 The HPP comprises about 50 teams organized in the Chromosome-centric C-HPP, the Biology and Diseasedriven B/D-HPP, and the Antibody, Mass Spectrometry, and Knowledgebase resource pillars. Our grand challenge is to use proteomics to bridge major gaps between evidence of genomic, epigenomic, and transcriptomic variation and diverse phenotypes. 3 The purpose of this article is to ensure common ground for all C-HPP and B/D-HPP teams for the assessment of progress on the protein parts list, updated approximately annually, for our search for "missing proteins", and for extensive characterization of proteins in networks and pathways. Understanding the extensive information available in the key data resources is valuable to many other researchers interested in knowing what proteins and what protein isoforms have been identified and characterized in various cell types, organs, and biofluids.
■ THE SEPTEMBER 2013 UPDATE OF THE HPP METRICS FOR THIS SPECIAL ISSUE
For the initial Journal of Proteome Research C-HPP special issue in January 2013, the HPP executive committee and investigators agreed on five standard baseline metrics for the whole proteome and for each chromosome, as of October 2012, and the respective thresholds for credible evidence. 1 These resources, metrics, and thresholds were Ensembl v69 for numbers of protein-coding genes; PeptideAtlas (canonical/1% FDR) and GPMdb (green) for standardized analyses of mass spectrometry data sets using TransProteomicPipeline and X!Tandem methods, respectively; Human Protein Atlas (high/medium score) for antibody-based protein identifications and expression profiles; and neXtProt (validated at "gold" protein level, corresponding to 1% FDR) for combined mass spectrometry, immunohistochemical, structural, or Edman sequence evidence. 5 Each resource has provided a chromosome-by-chromosome analysis as part of their engagement with the Human Proteome Project and C-HPP. The numbers across those five resources last year were 20 059 for Ensembl v69, 12 509 for PeptideAtlas, 14 300 for GPMdb, 10 794 for Human Protein Atlas, and 13 664 for neXtProt.
Here we update those metrics, chromosome-by-chromosome, to the time of the Yokohama HUPO Congress in September 2013. These metrics were useful for HPP discussions and workshops in Yokohama and for the many manuscripts being prepared for this January 2014 C-HPP special issue of the Journal of Proteome Research. As shown in summary rows at the bottom of Table 1 , there has been a substantial increase in the numbers of proteins identified: with a denominator of 20 115 neXtProt entries for presumed proteincoding genes, there are 15 646 entries validated at the protein expression level PE1 in neXtProt (78%). The corresponding figures are 14 012 in PeptideAtlas, 14 869 in GPMdb, and 10 976 in HPA. The HPA number reflects a new combination of high and moderate antibody-based protein identifications, now called "supportive" evidence, released as HPA version 12 on December 5, 2013 at www.proteinatlas.org. Last year, we used a very rough estimation of "missing proteins", which was the mean of neXtProt, PA, and GPMdb subtracted from the Ensembl number of genes, or 6568 (33%). That approach has been replaced by our pie chart analysis.
Both neXtProt and PeptideAtlas had notable increases in numbers in 2013, with 1982 and 1503 additional highconfidence entries, respectively. In the 2013 Journal of Proteome Research special issue, Farrah et al. reported that the Human Proteome Peptide Atlas lacked major data sets for liver, muscle, and kidney and membrane fractions, which were enriched in the "unseen proteins" category [4]; PeptideAtlas has been expanded partially by many new data sets and partially by the major project comparing the kidney, urine, and plasma proteomes (Farrah et al., this issue).
■ THE NEXTPROT AND UNIPROT/SWISSPROT SCHEME OF LEVELS OF EVIDENCE
The "protein evidence levels" used by neXtProt (and UniProt/ SwissProt) are classified in five categories (PE 1−5). PE1 signifies credible evidence of protein expression and identification by mass spectrometry, immunohistochemistry, 3D structure, or amino acid sequencing. PE2 recognizes transcript expression evidence, without evidence of protein expression. PE3 signifies the lack of protein or transcript evidence but the presence of protein evidence for a homologous protein in a related species. PE4 hypothesizes from gene models, and PE5 consists of "dubious" or "uncertain" genes that seemed to have some protein-level evidence in the past but since has been deemed doubtful. We have clear thresholds for PE1 protein evidence, as stated in the Introduction and Table 1 (neXtProt gold, PeptideAtlas 1% FDR, GPMdb green, and HPA supportive). Later we propose a threshold for PE2 transcript evidence. We recommend and implement a fresh approach to PE5, for which evidence is poor to absent, namely, to remove category PE5 from the denominator of protein-coding genes and expected proteins (below). As of September 2013, neXtProt has 15 646 at PE1, 3570 at PE2, 187 at PE3, 87 at PE4, and 638 at PE5.
All of our database resources have chromosome-specific displays to assist the C-HPP investigators; see www.neXtProt. org, www.peptideatlas.org, www.gpm.org, and www. proteinatlas.org as well as www.thehpp.org, www.c-hpp.org, and the C-HPP wiki at http://c-hpp.webhosting.rug.nl/tikiindex.php.
■ PIE CHART FRAMING THE QUEST FOR MISSING PROTEINS
In Yokohama, one of us (A.B.) presented the pie chart shown in Figure 1 , guiding our quest for the missing proteins. This chart also reveals some of the interactions and gaps between pairs of our core databases. Two-thirds of the pie (13 359) are proteins validated at the protein level in neXtProt (and UniProt/SwissProt) and present in PeptideAtlas; 1071 are validated in neXtProt and by additional proteomic (mass spectrometric) data but not in PeptideAtlas; 1216 are validated in neXtProt from antibody-capture, 3D structures in Protein Data Bank, or Edman sequencing but have no high-quality mass spec evidence reviewed by neXtProt; these include polypeptide hormones and cytokines and other proteins hard to solubilize or digest with trypsin or otherwise hard to detect by MS. That leaves two sectors. The first is called PE5 (above); these listed genes actually have very little credible evidence and are commonly described as "uncertain" or "dubious". After considerable discussion and a caution that a manual curation of each would be desirable, we decided to remove these 638 PE5 "genes" from the denominator of protein-coding genes. We also reviewed the discrepancies between protein entries in UniProtKB/SwissProt and neXtProt and gene entries in Ensembl, as discussed later. The final sector of proteins targets those awaiting experimental validation at the protein level, that is, PE 2 + 3 + 4 = 3844. Table 2 summarizes the results from all databases, by chromosome. It also reveals a few anomalies in the matching of proteins and genes. There are 25 nextProt entries not confidently mappable to any chromosome, including 7 PE1, 17 PE2 + 3 + 4, and 1 PE5 entries; in addition, there are 7 entries that are shared by more than 1 chromosome, including NX_Q6VEP3 (FAM138A, B, C, F) coded on chromosomes 1, 2, 9, and 19, and NX_Q6iEY1 (OReF16, F29, F3) on chromosomes 1 and 5. There are many other complications. Identical histone H4 proteins are produced from 14 genes and ubiquitin protein by 4 genes. There are bicistronic mRNAs; there are somatic rearrangements that generate immunoglobulins; there are proteins with two or more polypeptide chains from two or more genes (and sometimes chromosomes), representing "many to one" relationships; and there are a great many complexities arising from alternative splicing and gene fusions. Also, we should remember that "the human genome" is a "consensus" sequence; individuals vary in the number of copies of various genes, and there is evidence for active proteins from certain pseudogenes in certain individuals. In summary, Ensembl is not completely in sync with neXtProt annotation of protein-coding genes.
With extensive studies of presumed "non-coding RNAs", new small proteins are being found hidden in the 5′ or 3′ regions or made from the opposite strand of DNA; some of these are deduced from ENCODE evidence of transcription from regions of the genome where no gene had been detected. Most of these transcripts and a few resulting polypeptides lack evidence of conservation and fit no functional class, making their recognition suspicious. Bairoch's conclusion is appropriate: "extraordinary claims require extraordinary evidence".
There is a vast amount of annotation in neXtProt and the combined databases used by C-HPP and HPP. neXtProt as of September 2013 had 20 128 protein entries (a number which keeps declining) and 39 325 isoforms (a number that keeps rising). As noted at the bottom of Table 2 , the number of 2061  1600  1415  1521  1119  2  1240  1239  1029  909  962  685  3  1071  1076  877  764  818  634  4  769  763  613  529  566  398  5  862  867  696  624  668  496  6  1094  1108  902  795  784  616  7  938  944  706  660  680  520  8  709  701  553  472  500  383  9  821  821  616  544  567  403  10  762  763  592  528  574  452  11  1314  1321  926  791  845  659  12  1026  1030  842  730  787  609  13  328  328  266  236  251  186  14  625  626  503  445  472  372  15  614  609  457  427  456  328  16  839  831  660  614  671  498  17  1167  1167  951  847  907  648  18  276  278  227  195  219  175  19  1414  1424  1018  1028  1076  716  20  547  552  442  384  398  276  21  254  254  167  142  148  122  22  458  464  356  337  339  254  X  866  827  613  554  626 We recognize that there are additional data resources and data browsers being created around the world, some of which are highlighted in the C-HPP papers of 2013, including Proteome Browser, 6 CAPER 7 and CAPER2.0 (D. Wang et al., this issue), GenomewidePDB, 8 and Gene-centric Knowledgebase. 9 
■ STRATEGIES FOR SEARCHING FOR "MISSING

PROTEINS"
There are many explanations for missing proteins. Here we give an outline of approaches (Table 3) .
First, we systematically miss proteins expressed significantly only in unusual organs or cell types. Examples might be various regions of the brain, with extreme histologic and functional heterogeneity; nasal epithelium and olfactory cortex, with the very large family of (generally untranscribed) olfactory receptor genes; testis; and placenta. However, Martins-de-Souza et al. 10 reported only five proteins not previously identified by MS in an impressive study of the anterior temporal lobe and corpus callosum in human brains (mapped to chromosomes 4, 6, 11, 14, and 15). Multiple cultured cells from different cell lineages have shown relatively small numbers of cell-line specific proteins, with about 10 000 proteins in common and 20−100 proteins specific per cell line.
11−14 Fagerberg et al. 15 performed antibody-based protein profiling on 11 cell lines and found 27− 98 present in only one cell line and not in the others compared with 50% of 13 985 proteins found in all 11 cell lines. Placenta was reported in the 2013 Journal of Proteome Research C-HPP special issue to have 33 previously unreported proteins, of which only 13 were uniquely expressed in placenta. 16 Such studies show synergies between the C-HPP and B/D-HPP consortia.
A strong clue to the potential expression of proteins in particular tissues is the presence of substantial levels of the corresponding mRNA. Zhong et al. 17 and Q. Wang et al. (this issue) have emphasized the usefulness of measuring poly-Arich-mRNA in nascent chain complexes on polysomes, which they call the "translatome", reflecting the first and rate-limiting step for translation to proteins. They report 3−7% fewer transcripts in the translatome than in the transcriptome. The Human Protein Atlas has combined analysis of transcripts and detection of protein expression through immunohistochemistry with polyclonal antibodies raised against predicted epitopes of proteins. In the panel of cell lines and tissues used in the Human Protein Atlas, transcripts for a total of 18 845 proteincoding genes were detected. Danielsson et al. 18 emphasized that there are at least 411 cell types in the human body, including 145 different neuronal cell types. They also note that it is important to recognize a threshold for transcript evidence (typically RPKM >1 or >3), as used by the chromosome 17 team 19 (Menon et al., this issue), so as not to be misled by noisy results for very low abundance transcripts. As they stated, low abundance proteins have much higher risk of antibody crossreactivity/off-target binding at low affinity, generating falsepositives. Work presented in Yokohama by Uhlen showed a surprisingly high correlation between RNA and protein expression (Spearman correlation 0.96) with 46% of proteins omnipresent "housekeeping" proteins; 28% mixed tissue expression; 16% tissue or group specific; and 9% of genes lacking both transcripts and proteins. The tissue-specific or tissue-enriched set included 928 in testis, 340 in brain, 194 in adipose tissue, 104 in heart, and 68 in kidney.
Searching for mass spectrometry evidence of such proteins can employ Multiple Reaction Monitoring MS methods, as demonstrated by Chen et al. (this issue), who reported confirming 57 targeted proteins in normal human liver, of which 7 had no previous MS-based evidence. Proteogenomic approaches may be complementary, mapping individual peptides to their "genomic coding locations"; for example, an estimated 25% of tryptic peptides span exon boundaries and generally would be false-negatives. 20 Islam et al. (this issue) use Protannotator to suggest protein candidates based on nonhuman homologous proteins.
Second, there may be whole sets of proteins expressed only in early developmental stages in the embryo or fetus. Heck and collaborators 21 reported deep proteomic analyses of embryonic and induced pluripotent stem cell lines but found only relatively few unknown proteins. It is possible that a burst of additional proteins might occur at critical points in lineage-specific growth and development. Again, transcript expression and antibody- Table 3 . Strategies for Searching for Missing Proteins 1. Start from the tissue distribution of reported transcriptome expression 2. Consider early stages of life 3. Consider special stresses or other perturbations 4. Recognize low abundance of many proteins or transmembrane helical structures and sequences poor in tryptic cleavage sites; all of these will require more sensitive or different analytical methods 5. Seek more detailed information about highly homologous families of proteins and increase the sequence coverage, if feasible based detection might be guides for mass spectrometry methods. Third, it is quite likely that some families of genes and proteins are silent but can be activated under certain stresses. The Chinese Chromosome Proteome Consortium investigating chromosomes 1, 8, and 20 has studied the beta-defensin family of 38 genes; they encode antimicrobial polypeptides of considerable sequence diversity (Y. Liu et al., this issue; Q. Wang et al., this issue). Thirty of these genes are clustered in chromosomal regions 6p12.3, 8p23.1 (two blocks), 20p13, and 20q11.21. DEFB136 was detected by immunohistochemistry in 25/80 hepatic samples. Essentially all of the others were silent. DEFB1 and DEFBA104 were detected at mRNA and RNCmRNA levels, but no protein was detected. DEFB4A and DEFB4B have been reported to be induced by infectious and inflammatory stimuli.
Olfactory receptor genes are similarly silenced in humans. Olfaction is far more important in rodents and other mammalian species, yet humans have hundreds of olfactory receptor genes, of which a substantial percentage have degraded to pseudogene status.
Fourth, we recognize the importance of limit of detection with present methods, especially for highly complex tissue and biofluid specimens. All technologies and fractionation or depletion protocols that increase the sensitivity of detection will increase the prospects of identifying proteins at low concentrations. MRM or SISCAPA-MRM can be used to target specific proteins and extend the limit of detection. For many membrane-embedded proteins, solubilization is difficult and the protein sequence may not expose many or any tryptic cleavage sites, making detection of tryptic peptides unlikely or impossible. Examples of solute carrier channel proteins were highlighted in the comparative analysis of kidney, urine, and plasma proteomes, (Farrah et al., this issue). There are many proteins with unusual conformations and unusual sequences as well as peptides that may not be detected by standard methods. Farrah et al. 4 extensively annotated the "PA-unseen proteins", which were enriched for very hydrophobic, very basic, and membrane proteins. They described the striking case of the second most abundant transcript, 60S ribosomal protein L41, which has so many lysine and arginine residues that there are no tryptic peptides longer than two amino acids. Nevertheless, Muraoka et al. 22 recovered and identified 3282 membraneembedded proteins and mapped them to the 24 chromosomes as a service to all C-HPP teams.
Finally, there are large families of proteins or subfamilies with high sequence homology that may give overlapping matches to available tryptic peptides and thereby be excluded when one of the groups is chosen as a "representative protein" in the analysis. PeptideAtlas excludes additional protein matches if there is >80% sequence homology. Pfam, the leading protein family database (http://pfam.sanger.ac.uk/), defines protein family by sequence-based hidden Markov model search using HMMER3 alignment. 23 Pfam release 26.0 has 13 000 protein families. Detailed annotations on those proteins that have structures experimentally solved are available at SCOP, the Structural Classification of Proteins (http://scop.mrc-lmb.cam. ac.uk/scop/), with a hierarchy of species, protein, family, superfamily, fold, and class. 24 There is one more way in which we can reduce the number of missing proteins to be found. We discussed above the 638 dubious genes or pseudogenes, which we have decided should be removed from the denominator of protein-coding genes.
That reduces the number of missing proteins to the proteins with evidence levels 2, 3, or 4, a total of 3844 (Table 2, Figure  1 ). The new denominator is 20 128 (column 3 of Table 2 ) − 638 (PE5, column 8 of Table 2) = 19 490. There is also a path that requires special caution, which is dipping into the less confidently identified proteins in silver or bronze neXtProt, yellow or red GPMdb, 5% FDR in PeptideAtlas, or low-reliability immunostaining in HPA. Such reports may be precursors to definitive findings with more sensitive or more accurate methods, as has been demonstrated with "one-hit wonders" when a more advanced mass spectrometer was utilized. 25 For the HPP, however, we want to avoid any confusion about the HPP thresholds for "counting" proteins.
■ DATA SET SUBMISSIONS
The HPP and C-HPP leadership published guidelines and secured agreement from the participating investigators to upload their raw spectra, full data sets, and metadata via ProteomeXchange to EBI/PRIDE for MS/MS data and ISB/ SRM Atlas/PASSEL for SRM/MRM datasets. (J. A. Vizcaino et al., Nat. Biotechnol., in press). Authors were advised to place the PXD identifier at the end of the Abstract and the relevant details in the Methods; many have done so. It is very important to have full access to the data sets from the HPP, of course. 
■ CONCLUDING REMARK
